Diabetes and the endothelium

Acta Clinica Belgica

Volumn 62, Issue 2, 2007, Pages 97-101

  Hermans, Michel P ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

AGE; Diabetes; Endothelium; Mitochondria; PARP; PKC; Superoxide

Indexed keywords

ADIPOCYTOKINE; ALDEHYDE REDUCTASE; GLUCOSE TRANSPORTER 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE C; SUPEROXIDE; VASCULOTROPIN;

DIABETES MELLITUS; DIABETIC ANGIOPATHY; DNA DAMAGE; DYSLIPIDEMIA; ELECTRON TRANSPORT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; GENETIC SUSCEPTIBILITY; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW;

EID: 34248154187     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2007.017     Document Type: Review

References (17)

1. Larger E, Roussel R. Physiopathologie de la micro-angiopathie diabétique. In : Traité de Diabétologie, A. Grimaldi ed. Flammarion-Sciences, pp 521-35, 2005.
2. nd edition. Lippincott, Williams & Wilkins, 2002.
3. King GL, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996; 25: 255-70.
4. Kaiser N, Sasson S, Feener EP, Boukobza-Vardi N, Higashi S, Moller DE, Davidheiser S, Przybylski RJ, King GL. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 1993 ; 42: 80-9.
5. Mandarino LJ, Finlayson J, Hassell JR. High glucose downregulates glucose transport activity in retinal capillary pericytes but not endothelial cells. Invest Ophthalmol Vis Sci 1994 ; 35: 964-72.
6. Sone H, Deo BK, Kumagai AK. Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells. Invest Ophthalmol Vis Sci 2000; 41: 1876-84.
7. Busik JV, Olson LK, Grant MB, Henry DN. Glucose-induced activation of glucose uptake in cells from the inner and outer blood-retinal barrier. Invest Ophthalmol Vis Sci 2002; 43: 2356-63.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
9. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005; 54:1615-25.
10. The PKC-DRS Study Group. The Effect of Ruboxistaurin on Visual Loss in Patients With Moderately Severe to Very Severe Nonproliferative Diabetic Retinopathy. Initial Results of the Protein Kinase C β Inhibitor Diabetic Retinopathy Study (PKC-DRS) Multicenter Randomized Clinical Trial. Diabetes 2005 ; 54: 2188-97.
11. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005 ; 28: 2686-90.
12. Du X, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M. Hyperglycemiaglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci 2000 ; 97: 12222-6.
13. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-36.
14. Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J 2004; 18: 805-15.
15. Varghese Z, Moorhead JF, Ruan XZ. The PPAR ligand fenofibrate: meeting multiple targets in diabetic nephropathy. Kidney Int 2006; 69: 1490-1.
16. Park CW, Kim HW, Ko SH, Chung HW, Lim SW, Yang CW, Chang YS, Sugawara A, Guan YF, Breyer MD. Accelerated diabetic nephropathy in mice lacking the Peroxisome Proliferator-Activated Receptor α. Diabetes 2006; 55: 885-3.
17. Varet J, Vincent L, Mirshahi P, Pille JV, Legrand E, Opolon P, Mishal Z, Soria J, Li H, Soria C. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell. Mol. Life Sci 2003; 60: 810-9.